UK Markets close in 3 hrs 9 mins

Global Biologic Therapeutic Drugs Market (2021 to 2025) - Featuring Amgen, Baxter and China Biologic Products Among Others

Research and Markets
·5-min read

Dublin, April 02, 2021 (GLOBE NEWSWIRE) -- The "Biologic Therapeutic Drugs: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

The current report offers a detailed picture of the biologics market. This report highlights the current and future market potential for biologics and provides a detailed analysis of the competitive environment, regulatory scenario, drivers, restraints, opportunities and trends in the market. The report also covers market projections through 2025, as well as key market players.

This report details market shares for biologics based on product and geography. Based on product, the market is segmented into therapeutic proteins, vaccines and other segments.

Based on geography, the market has been segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. Detailed analyses of major countries (the U.S., Canada, Germany, the U.K., France, Spain, Italy, Japan, China and India) are covered in regional segments. For market estimates, data has been provided for 2020 as the base year, with forecasts for 2020 through 2025. Estimated values are based on product manufacturers' total revenues. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.

Report Includes:

  • 22 data tables and 26 additional tables

  • An overview of the global market for biologic therapeutic drugs

  • Analyses of the global market trends, with data from 2018-2020, and projections of compound annual growth rates (CAGRs) through 2025

  • Evaluation of market size and market forecast; and detailed review of drivers, challenges, and opportunities affecting the global market growth

  • Detailed description of product segments of biologic therapeutic drugs, such as therapeutic proteins, vaccines, cell therapy, gene therapy, blood plasma products, and others

  • Assessment of the competitive environment, with a special focus on how new products and technologies are influencing the current standards of care

  • Country specific data and analysis for the United States, Canada, Germany, U.K., France, Italy, Spain, Russia, China, India, Japan and other emerging economies

  • Impact analysis of COVID-19 on the entire life sciences industry as well as on biologic therapeutic drugs market

  • Profiles of current market leaders, as well as companies with innovative products poised to advance within the forecast period

  • Company profile descriptions of major biologic therapeutic drugs manufacturers, including Amgen Inc., Baxter International, CSL Ltd., Eli Lilly and Co., F. Hoffmann-La Roche, GlaxoSmithKline Plc, Novartis and Sanof

The growth of the global market is attributed to the rising prevalence of chronic and acute diseases and the growing global geriatric population.

The global biologic therapeutic drug market is segmented in this report by product and region.

Reasons for Doing This Study:

  • The biologics market is wide-ranging and has important implications for the future of medicine and industry advancement. For companies with an effective strategy, market opportunities await. Importantly, the ability to develop an effective strategy begins where opportunity exists and ends with how to effectively execute a plan to capture profit from such opportunities.

  • Market growth has been spurred by the need for a more extensive pipeline from drug companies, attractive targets against challenging diseases, a push by companies to pursue biosimilars (a biologic like another biologic that has already been authorized for use) and manufacturing technologies that reduce the cost to produce profitable products.

  • This report seeks to address the critically important topics of changing market dynamics, emerging players and technologies, strategies for accessing emerging markets, and specific disease segments and geographies to allocate resources and make effective decisions.

Key Topics Covered:

Chapter 1 Introduction

  • Introduction

  • Study Goals and Objectives

  • Reasons for Doing This Study

  • Scope of Report

  • Information Sources

  • Methodology

  • Geographic Breakdown

  • Analyst's Credentials

  • Custom Research

  • Related Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • Biopharmaceutical Industry Structure

  • Origins of Biotechnology

  • Involvement of Large Pharmaceutical Companies

  • Overview of Biologics

  • Biologics Manufacturing

  • Biopharmaceutical Manufacturing Process

  • The Preparation Process

  • Expression Systems for Therapeutic Protein Production

  • E. coli Advantages for Microbial Production

  • Mammalian Cell Therapeutic Protein Production

  • FDA Regulation of Biologics

Chapter 4 Impact of COVID-19 Pandemic

  • Introduction

  • Short-Term Impact

  • Long-Term Impact

  • Delayed Approvals for Non-COVID-Related Pharmaceutical Products

  • Self-Sufficiency in Pharma Industry

  • Progression of COVID-19

  • Government Expenditures on COVID-19

  • Social Impact of COVID-19

  • Impact on Insurance Providers

  • Impact on Health Technology Assessment

  • Changes in Consumption Trends in Health-Related Products

Chapter 5 Market Dynamics

  • Market Drivers

  • Overview

  • Rising Prevalence of Chronic Diseases

  • Advancement in Biologics

  • Growing Geriatric Population

  • Market Restraints

  • Emergence of Biosimilars

  • Market Opportunities

  • Opportunities in Emerging Nations

Chapter 6 Market Breakdown by Product Segment

  • Global Market for Biologic Therapeutic Drugs by Product Segment

  • Therapeutic Proteins

  • Vaccines

  • Others

Chapter 7 Market Breakdown by Region

  • Global Market for Biologic Therapeutic Drugs by Region

  • North America

  • Europe

  • Asia-Pacific

  • Latin America

  • Middle East and Africa

Chapter 8 Competitive Landscape

  • Porter's Five Forces Analysis

  • Bargaining Power of Suppliers

  • Bargaining Power of Buyers

  • Threat of New Entrants

  • Threat of Substitutes

  • Competitive Rivalry/Degree of Competition

Chapter 9 Company Profiles

  • Amgen Inc.

  • Baxter

  • China Biologic Products Inc.

  • Csl Ltd.

  • Dendreon Pharmaceuticals Llc

  • Eli Lilly And Co.

  • F. Hoffmann-La Roche Ltd.

  • Glaxosmithkline Plc

  • Glycotope Gmbh

  • Grifols S.A.

  • JSC Pharmstandard

  • Kedrion S.P.A.

  • Novartis Ag

  • Octapharma Ag

  • Reliance Life Sciences

  • Sanofi

  • Teva Pharmaceutical Industries Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/17hxiv

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900